Maqola

POS-246 EVALUATION OF THE USE OF RIVAROXABAN IN PATIENTS WITH STAGE 4 CKD IN AF

Ranokhon IgamberdievaTashkent pediatric medical institute, Internal medicine, Tashkent, UzbekistanSherzod AbdullaevRepublican Scientific and Practical Medical Center of Nephrology and Kidney Transplantation, Immunogenetics, Tashkent, Uzbekistan

Kidney International Reportsjournal2022en

ABI

Annotatsiya

Anticoagulant therapy is the standard for the prevention of thromboembolic complications (TEC) and, first of all, acute cerebrovascular accident (ACVA) in atrial fibrillation (AF). The combination of advanced chronic kidney disease (CKD) and AF leads to an even greater increase in the risk of TEO, but is also a risk factor for various bleeding. Clinical data on the use of new oral anticoagulants (NOACs) in this group of patients are limited, which determines the relevance of studies in comparison with vitamin K antagonists.

Mavzular

Atrial Fibrillation Management and Outcomes

Identifikatorlar

DOI: 10.1016/j.ekir.2022.01.265

Iqtiboslar va manbalar

0 ta iqtibos0 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar · Tez orada